Atom Bioscience has mainly focused on the new drug discovery and development on the treatment of metabolic disease. The management team is composed of senior researchers with rich experience in discovery and development in the US, UK, and China. Atom Bioscience has extensive cooperation with global pharmaceutical companies and research organizations.
Atom Bioscience develops several pipelines. Among them, a novel compound ABP-671 for gout treatment showed a great inhibition of human renal urate transporter 1 (hURAT1) whose function is to control the reabsorption of uric acid by the kidneys. ABP-671 is currently under phase 1 clinical trials in the US. It has shown superior reductions in serum uric acid in the recent first human study, which is significantly better than market gout drugs. ABP-671 may replace the current uricosuric agents to be the most potent and safe drug for the treatment of gout and hyperuricemia worldwide. Atom Bioscience also dedicates to discovering and developing novel drugs to treat NASH, cancers, etc. These compounds are under pre-clinical development, will enter clinical trials in 2020.
Atom Bioscience has completed over 10 million USD financing at Round Angel, A and A+. Investors are KAITAI Capital, YouChoose Capital, Ch-gemstone Capital, etc.